Nature Communications (Dec 2021)
Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer
- Clemens Hinterleitner,
- Jasmin Strähle,
- Elke Malenke,
- Martina Hinterleitner,
- Melanie Henning,
- Marco Seehawer,
- Tatjana Bilich,
- Jonas Heitmann,
- Martina Lutz,
- Sven Mattern,
- Sophia Scheuermann,
- Marius Horger,
- Stefanie Maurer,
- Juliane Walz,
- Falko Fend,
- Rupert Handgretinger,
- Christian Seitz,
- Bettina Weigelin,
- Stephan Singer,
- Helmut Salih,
- Oliver Borst,
- Hans-Georg Kopp,
- Lars Zender
Affiliations
- Clemens Hinterleitner
- Department of Medical Oncology & Pneumology (Internal Medicine VIII), University Hospital Tuebingen
- Jasmin Strähle
- Department of Hematology, Oncology and Immunology, University Hospital Tuebingen
- Elke Malenke
- Department of Pediatric Hematology and Oncology, University Hospital Tuebingen
- Martina Hinterleitner
- Department of Medical Oncology & Pneumology (Internal Medicine VIII), University Hospital Tuebingen
- Melanie Henning
- Department of Medical Oncology & Pneumology (Internal Medicine VIII), University Hospital Tuebingen
- Marco Seehawer
- Department of Medical Oncology & Pneumology (Internal Medicine VIII), University Hospital Tuebingen
- Tatjana Bilich
- DFG Cluster of Excellence 2180 ‘Image-guided and Functional Instructed Tumor Therapy’ (iFIT), University of Tuebingen
- Jonas Heitmann
- DFG Cluster of Excellence 2180 ‘Image-guided and Functional Instructed Tumor Therapy’ (iFIT), University of Tuebingen
- Martina Lutz
- DFG Cluster of Excellence 2180 ‘Image-guided and Functional Instructed Tumor Therapy’ (iFIT), University of Tuebingen
- Sven Mattern
- Department of Pathology and Neuropathology, University Hospital Tuebingen
- Sophia Scheuermann
- DFG Cluster of Excellence 2180 ‘Image-guided and Functional Instructed Tumor Therapy’ (iFIT), University of Tuebingen
- Marius Horger
- Department of Radiology, University Hospital Tuebingen
- Stefanie Maurer
- DFG Cluster of Excellence 2180 ‘Image-guided and Functional Instructed Tumor Therapy’ (iFIT), University of Tuebingen
- Juliane Walz
- DFG Cluster of Excellence 2180 ‘Image-guided and Functional Instructed Tumor Therapy’ (iFIT), University of Tuebingen
- Falko Fend
- Department of Pathology and Neuropathology, University Hospital Tuebingen
- Rupert Handgretinger
- DFG Cluster of Excellence 2180 ‘Image-guided and Functional Instructed Tumor Therapy’ (iFIT), University of Tuebingen
- Christian Seitz
- DFG Cluster of Excellence 2180 ‘Image-guided and Functional Instructed Tumor Therapy’ (iFIT), University of Tuebingen
- Bettina Weigelin
- Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tuebingen
- Stephan Singer
- Department of Pathology and Neuropathology, University Hospital Tuebingen
- Helmut Salih
- DFG Cluster of Excellence 2180 ‘Image-guided and Functional Instructed Tumor Therapy’ (iFIT), University of Tuebingen
- Oliver Borst
- University Hospital, Department of Cardiology and Angiology, Eberhard Karls University of Tuebingen
- Hans-Georg Kopp
- Robert-Bosch-Hospital, Department of Molecular and Pneumological Oncology
- Lars Zender
- Department of Medical Oncology & Pneumology (Internal Medicine VIII), University Hospital Tuebingen
- DOI
- https://doi.org/10.1038/s41467-021-27303-7
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 16
Abstract
The definition of biomarkers to predict therapy responses to immune-checkpoint inhibitors represent an unmet clinical need. Here the authors provide evidences that platelet-derived PD-L1 could serve as a prognostic and predictive biomarker in patients with non-small cell lung cancer.
